Merck KGaA

BST:MRKC Stock Report

Market Cap: €60.1b

Merck KGaA Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Belen Garijo Lopez

Chief executive officer

€10.5m

Total compensation

CEO salary percentage14.2%
CEO tenure9.9yrs
CEO ownershipn/a
Management average tenure6.2yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Belen Garijo Lopez's remuneration changed compared to Merck KGaA's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

€3b

Jun 30 2024n/an/a

€3b

Mar 31 2024n/an/a

€3b

Dec 31 2023€11m€2m

€3b

Sep 30 2023n/an/a

€3b

Jun 30 2023n/an/a

€3b

Mar 31 2023n/an/a

€3b

Dec 31 2022€11m€2m

€3b

Sep 30 2022n/an/a

€3b

Jun 30 2022n/an/a

€3b

Mar 31 2022n/an/a

€3b

Dec 31 2021€9m€1m

€3b

Sep 30 2021n/an/a

€3b

Jun 30 2021n/an/a

€3b

Mar 31 2021n/an/a

€2b

Dec 31 2020€7m€1m

€2b

Sep 30 2020n/an/a

€2b

Jun 30 2020n/an/a

€1b

Mar 31 2020n/an/a

€2b

Dec 31 2019€6m€1m

€1b

Sep 30 2019n/an/a

€1b

Jun 30 2019n/an/a

€1b

Mar 31 2019n/an/a

€938m

Dec 31 2018€7m€1m

€1b

Sep 30 2018n/an/a

€2b

Jun 30 2018n/an/a

€2b

Mar 31 2018n/an/a

€2b

Dec 31 2017€6m€1m

€3b

Compensation vs Market: Belen's total compensation ($USD10.98M) is above average for companies of similar size in the German market ($USD4.86M).

Compensation vs Earnings: Belen's compensation has been consistent with company performance over the past year.

CEO

Belen Garijo Lopez (64 yo)

9.9yrs

Tenure

€10,527,000

Compensation

Ms. Belen Garijo Lopez, M.D., is Chair of Executive Board and Chief Executive Officer of MERCK Kommanditgesellschaft auf Aktien since May 01, 2021. She served as Vice Chairman of the Executive Board and De...

Leadership Team

NamePositionTenureCompensationOwnership
Belen Garijo Lopez
Chair of Executive Board & CEO9.9yrs€10.53mno data
Helene von Roeder
CFO & Member of Executive Board1.4yrs€1.23mno data
Kai Beckmann
CEO of Electronics & Member of the Executive Board13.7yrs€8.26mno data
Peter Guenter
CEO of Healthcare Business & Member of Executive Board3.9yrs€5.58mno data
Matthias Heinzel
CEO of Life Science Sector & Member of Executive Board3.7yrs€5.22mno data
Barbara Weiland
Chief Compliance Officer5.4yrsno datano data
Dietmar Eidens
Head of the Global HR Business Partner Organization9.9yrsno datano data
Frank Gotthardt
Head of Corporate & Government Relations - Europe15.5yrsno datano data
Marc Horn
Head of Life Science Controllingno datano datano data
Michael Heckmeier
Head of the Display Materials Business Unit for Performance Materials7.7yrsno datano data
Hans-Joachim Neumann
Head of Integrated Supply Chain6.2yrsno datano data
Tina Sandmann
Head of Internal Auditing5.4yrsno datano data

6.2yrs

Average Tenure

57yo

Average Age

Experienced Management: MRKC's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dietmar Oeter
Independent Member of Supervisory Board10.6yrs€50.80kno data
Alexander Putz
Member of Supervisory Board4.6yrs€50.80kno data
Stefan Palzer
Supervisory Board Memberless than a yearno datano data
Barbara Lambert
Independent Member of Supervisory Board1.3yrs€30.50kno data
Sascha Held
Vice Chair of Supervisory Board5.7yrs€89.30kno data
Michael Kleinemeier
Independent Chairman of Supervisory Board5.7yrs€50.80kno data
Anne Lange
Independent Member of Supervisory Board5.7yrs€50.80kno data
Christian Raabe
Independent Member of Supervisory Board5.7yrs€65.80kno data
Daniel Thelen
Independent Member of Supervisory Board5.7yrs€65.80kno data
Simon Thelen
Independent Member of Supervisory Board5.7yrs€50.80kno data
Birgit Biermann
Member of Supervisory Board2.4yrs€50.80kno data
Katja Vila
Supervisory Board Memberless than a yearno datano data

5.7yrs

Average Tenure

55yo

Average Age

Experienced Board: MRKC's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 09:50
End of Day Share Price 2024/09/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Merck KGaA is covered by 60 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Gerhard SchwarzBaader Helvea Equity Research
Odile RundquistBaader Helvea Equity Research